Openly accessible

EpCAM immunotherapy versus specific targeted delivery of drugs

Macdonald, Joanna, Henri, Justin, Roy, Kislay, Hays, Emma, Bauer, Michelle, Veedu, Rakesh Naduvile, Pouliot, Normand and Shigdar, Sarah 2018, EpCAM immunotherapy versus specific targeted delivery of drugs, Cancers, vol. 10, no. 1, pp. 1-13, doi: 10.3390/cancers10010019.

Attached Files
Name Description MIMEType Size Downloads
macdonald-epcamimmunotherapy-2018.pdf Published version application/pdf 1.78MB 1

Title EpCAM immunotherapy versus specific targeted delivery of drugs
Author(s) Macdonald, Joanna
Henri, Justin
Roy, Kislay
Hays, Emma
Bauer, Michelle
Veedu, Rakesh Naduvile
Pouliot, Normand
Shigdar, SarahORCID iD for Shigdar, Sarah orcid.org/0000-0001-8084-8447
Journal name Cancers
Volume number 10
Issue number 1
Start page 1
End page 13
Total pages 13
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2018-01-12
ISSN 2072-6694
Keyword(s) EpCAM
antibody
aptamer
cancer
immunotherapy
therapeutics
Science & Technology
Life Sciences & Biomedicine
Oncology
CELL-ADHESION MOLECULE
TUMOR-ASSOCIATED ANTIGEN
MONOCLONAL-ANTIBODY 17-1A
CANCER-THERAPY
BREAST-CANCER
SOLID TUMORS
COLON-CANCER
MEDIATED CYTOTOXICITY
CLINICAL DEVELOPMENT
MACROCYCLIC-PEPTIDE
Summary The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.
Language eng
DOI 10.3390/cancers10010019
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, The Authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30110157

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 3 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 13 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Mon, 09 Jul 2018, 11:25:25 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.